CancerDrs

Lung Cancer clinical trials in New York

101 actively recruiting lung cancer trials at 43 sites across New York.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in New York:
  • Roswell Park Cancer Institute — Buffalo, New York
  • Memorial Sloan Kettering Commack — Commack, New York
  • Mary Imogene Bassett Hospital — Cooperstown, New York
  • The Cancer Institute at Saint Francis Hospital — East Hills, New York
  • Arnot Ogden Medical Center/Falck Cancer Center — Elmira, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in New York:
  • Roswell Park Cancer Institute — Buffalo, New York
  • Memorial Sloan Kettering Commack — Commack, New York
  • The Cancer Institute at Saint Francis Hospital — East Hills, New York
  • Glens Falls Hospital — Glens Falls, New York
  • Memorial Sloan Kettering Westchester — Harrison, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in New York:
  • New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
  • NYU Langone Hospital - Brooklyn — Brooklyn, New York
  • Memorial Sloan Kettering Commack — Commack, New York
  • Memorial Sloan Kettering Westchester — East White Plains, New York
  • The New York Hospital Medical Center of Queens — Flushing, New York
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in New York:
  • New York Oncology Hematology - Albany Medical Center — Albany, New York
  • Local Institution - Unk077 — Rhinebeck, New York
  • Montefiore Medical Center — The Bronx, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Sites in New York:
  • Montefiore Medical Center - Montefiore Medical Park — The Bronx, New York
  • White Plains Hospital — White Plains, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC)…

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in New York:
  • Research Site — Buffalo, New York
  • Research Site — East Syracuse, New York
  • Research Site — Westbury, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in New York:
  • New York Oncology Hematology, P.C. ( Site 4012) — Albany, New York
  • Memorial Sloan-Kettering Cancer Center at Commack ( Site 4055) — Commack, New York
  • Memorial Sloan Kettering - Westchester ( Site 4058) — Harrison, New York
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island-Clinical Research Department ( Site 0095) — Mineola, New York
  • The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 4053) — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in New York:
  • Research Site — Stony Brook, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in New York:
  • Roswell Park Cancer Institute ( Site 0184) — Buffalo, New York
  • Hematology-Oncology Associates of CNY ( Site 0164) — East Syracuse, New York
  • The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216) — New York, New York
  • Icahn School of Medicine at Mount Sinai ( Site 0116) — New York, New York
  • Memorial Sloan Kettering Cancer Center ( Site 0137) — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in New York:
  • Montefiore Einstein Cancer Center — The Bronx, New York
  • Clinical Research Alliance — Westbury, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361497
Sites in New York:
  • Local Institution - 0606 — New York, New York
  • Local Institution - 0339 — Westbury, New York
  • Local Institution - 0909 — Westbury, New York
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in New York:
  • Suny-Stony Brook University Cancer Center — Stony Brook, New York
  • White Plains Hospital — White Plains, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in New York:
  • Research Site — Brooklyn, New York
  • Research Site — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in New York:
  • Weill Medical College of Cornell University — New York, New York
  • Memorial Sloan-Kettering Cancer Center — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treat…

Sponsor: BioNTech SE
NCT ID: NCT06712355
Sites in New York:
  • White Plains Hospital — White Plains, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung…

Sponsor: Bayer
NCT ID: NCT06452277
Sites in New York:
  • R.J. Zuckerberg Cancer Center — New Hyde Park, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimuma…

Sponsor: AstraZeneca
NCT ID: NCT06097728
Sites in New York:
  • Research Site — Commack, New York
  • Research Site — Valhalla, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…

Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in New York:
  • Clinical Research Alliance — Westbury, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants …

Sponsor: ArriVent BioPharma, Inc.
NCT ID: NCT07185997
Sites in New York:
  • Northwell Health/R.J. Zuckerberg Cancer Center — Lake Success, New York
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in…

Sponsor: Nuvation Bio Inc.
NCT ID: NCT07154706
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in New York:
  • Roswell Park Cancer Institute — Buffalo, New York
  • University of Rochester — Rochester, New York
  • Wilmot Cancer Institute at Webster — Webster, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% …

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT05609578
Sites in New York:
  • Local Institution - 017-080 — Babylon, New York
  • Local Institution - 017-088 — Brooklyn, New York
  • Hematology-Oncology Associates of Central New York - Brittonfield - East Syracuse — East Syracuse, New York
  • Local Institution - 017-087 — New Hyde Park, New York
  • Local Institution - 017-085 — New York, New York
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in New York:
  • Northwell Health — Lake Success, New York
  • Laura & Isaac Perlmutter Cancer Center at NYC Langone Health — New York, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • North Shore Hematology Oncology Associate P.C. DBA New York Cancer and Blood Specialists — Shirley, New York
View on ClinicalTrials.gov →

Showing 25 of 101 trials with sites in New York. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25